2025-03-12 11:01:33
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Piramal Phamra Ltd reports consolidated loss of Rs. 37.34 crores in Q2 FY2023
Posted On : 2022-11-09 08:56:17( TIMEZONE : IST )
Piramal Pharma Limited has reported Consolidated financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 1766.23 crores during the period ended September 30, 2022 as compared to Rs. 1553.84 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. -37.34 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. -109.05 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. -0.31 for the period ended September 30, 2022 as compared to Rs. -0.92 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 1766.23 crs | ₹1553.84 crs |  13.67% |
| Net Profit | ₹-37.34 crs | ₹-109.05 crs |  65.76% |
| EPS | ₹-0.31 | ₹-0.92 | 66.30% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 1766.23 crores during the period ended September 30, 2022 as compared to Rs.1595.45 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.-37.34 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.36.56 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.-0.31 for the period ended September 30, 2022 as compared to Rs.0.31 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 1766.23 crs | ₹1595.45 crs | 10.70% |
| Net Profit | ₹-37.34 crs | ₹36.56 crs |  -202.13% |
| EPS | ₹-0.31 | ₹0.31 | -200.00% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.3320.07 crores during the 6 Months period ended September 30, 2022 as compared to Rs.2925.72 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.-146.39 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.8.53 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.-1.23 for the 6 Months period ended September 30, 2022 as compared to Rs.0.07 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹3320.07 crs | ₹2925.72 crs | 13.48% |
| Net Profit | ₹-146.39 crs | ₹8.53 crs | -1,816.18% |
| EPS | ₹-1.23 | ₹0.07 | -1,857.14% |
Shares of Piramal Pharma Limited was last trading in BSE at Rs. 163.95 as compared to the previous close of Rs. 169.50. The total number of shares traded during the day was 495822 in over 9323 trades.
The stock hit an intraday high of Rs. 172.55 and intraday low of 161.10. The net turnover during the day was Rs. 82206782.00.
